H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target of $90.00.
Patrick Trucchio has assigned a Buy rating to Arrowhead Pharmaceuticals based on a multifaceted evaluation of the company’s performance and strategic milestones. His positive outlook is particularly influenced by Arrowhead’s strong execution across various programs, with significant confidence in reaching their ambitious “20 in ’25” strategy, which aims to have 20 drugs in development or on the market by 2025. The company’s recent achievements, including the clearance of a safety hurdle in their pulmonary platform and the advancement of their lead cardio-metabolic compounds, plozasiran and zodasiran, underscore this progress. Furthermore, the possibility of plozasiran becoming Arrowhead’s first commercial product in 2025, if approved, presents a pivotal transition from clinical to commercial stages, enhancing shareholder value.
In addition to the strategic execution, near-term catalysts such as the de-risking of the pulmonary platform and the anticipated outcomes trial for their cardio-metabolic compounds contribute to the positive rating. Arrowhead’s reliance on non-dilutive funding sources and the robust pipeline of clinical-stage programs—15 in total, with 10 wholly-owned and five developed with partners—further support the company’s strong prospects. The ongoing nomination of new drug candidates and filing of Clinical Trial Applications (CTAs) across various tissue types, paired with Arrowhead’s productive use of their TRiM and RNA interference (RNAi) platforms, exemplify the company’s commitment to innovation and potential for significant value creation for its investors.
According to TipRanks, Trucchio is an analyst with an average return of -19.7% and a 26.84% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Altimmune, and Cybin.
In another report released yesterday, Bank of America Securities also initiated coverage with a Buy rating on the stock with a $29.00 price target.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arrowhead Pharmaceuticals (ARWR) Company Description:
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Read More on ARWR:
